Erika Lisabeth, Ph.D.

Dr. Lisabeth is an experienced biochemist and molecular biologist interested in the molecular mechanisms that lead to disease. Her post-doctoral work demonstrated that somatic mutations identified in cancer patients inactivate the EphA3 receptor tyrosine kinase, an unusual consequence of kinase mutations. In her graduate studies at UCSD, she characterized the degradation pathway of an inhibitor of the NF-KB transcription factor.

She has broad technical abilities, which include experience in recombinant protein purification and macromolecular crystallization. Her outgoing and friendly personality and inherent leadership qualities have fostered new and productive collaborations in the past, and most certainly will in the future.